Guo Huangda, Fan Meng, Hou Tianjiao, Li Yixin, Wang Siyue, Wang Xueheng, Peng Hexiang, Wang Mengying, Wu Tao, Zhang Yumei
Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China.
Key Laboratory of Epidemiology of Major Diseases (Peking University), Ministry of Education, Beijing 100191, China.
Foods. 2023 Dec 12;12(24):4451. doi: 10.3390/foods12244451.
Strategies to stabilize and support overall infant health by increasing the number of in the infant gut are of interest, but few studies have systematically addressed this issue. We aimed to evaluate the efficacy and safety of use in infants using meta-analysis.
We searched PubMed, EMBASE, Cochrane Library of Systematic Reviews, and SinoMed for publications until 27 July 2022. The main outcomes of interest were weight gain, risk of necrotizing enterocolitis (NEC), and adverse events. Two authors independently performed study screening, risk of bias assessment, and data extraction. Outcome data were extracted from each included study and combined using mean difference (MD) or risk ratio (RR) and finally combined using a fixed-effect model or random-effect model.
A total of 4481 relevant studies were identified, of which 15 were found to be eligible for randomized controlled trials and were included in the meta-analysis. The combined extracted data showed that the intervention group containing had a significantly lower risk of NEC (RR = 0.539, 95% CI: 0.333, 0.874) compared to the control group. There was no statistical difference between the intervention and control groups regarding weight gain (MD = 0.029, 95% CI: -0.032, 0.090), the occurrence of adverse events (RR = 0.986, 95% CI: 0.843, 1.153), and serious adverse events (RR = 0.881, 95% CI: 0.493, 1.573).
may significantly reduce the risk of NEC in infants as well as being safe; thus, further research evidence is needed on whether there is a benefit on weight gain.
通过增加婴儿肠道内[具体物质]数量来稳定和支持婴儿整体健康的策略备受关注，但很少有研究系统地探讨这一问题。我们旨在通过荟萃分析评估[具体物质]在婴儿中使用的疗效和安全性。
我们检索了PubMed、EMBASE、Cochrane系统评价图书馆和中国生物医学文献数据库，检索截至2022年7月27日的出版物。主要关注的结果是体重增加、坏死性小肠结肠炎（NEC）风险和不良事件。两位作者独立进行研究筛选、偏倚风险评估和数据提取。从每项纳入研究中提取结局数据，并使用均值差（MD）或风险比（RR）进行合并，最后使用固定效应模型或随机效应模型进行汇总。
共识别出4481项相关研究，其中15项被认为符合随机对照试验的纳入标准，并被纳入荟萃分析。合并提取的数据显示，与对照组相比，含有[具体物质]的干预组发生NEC的风险显著降低（RR = 0.539，95% CI：0.333，0.874）。干预组和对照组在体重增加（MD = 0.029，95% CI：-0.032，0.090）、不良事件发生率（RR = 0.986，95% CI：0.843，1.153）和严重不良事件发生率（RR = 0.881，95% CI：0.493，1.573）方面无统计学差异。
[具体物质]可能显著降低婴儿发生NEC的风险且安全性良好；因此，关于其对体重增加是否有益还需要进一步的研究证据。
